Neal Rosen: Featured News

Neal Rosen: Featured News

Share
Print
Share
Print
In the Clinic
Piro Lito, Bob Li, and Neal Rosen in the lab
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
Scott Lowe and Neal Rosen
Knocking Out KRAS-Mutant Cancers with a One-Two Punch
A new approach aims to combine two existing targeted therapy drugs to attack lung cancer and pancreatic cancer with mutations in the hard-to-target gene KRAS.
In the Lab
Colored x-ray of lung cancer
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Researchers are developing uses for a drug that could benefit many people with lung cancer.
In the Clinic
Memorial Sloan Kettering medical oncologist Andrea Cercek
FDA Approval Gives Hope to Some People with Advanced Colorectal Cancer
A new treatment is approved for an especially aggressive kind of colorectal cancer.
In the Lab
MSK investigators Joan Massagué and Anna Obenauf
Outsmarting Cancer’s Survival Skills
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
Profile
Pictured: David Solit
At Work: Physician-Scientist David Solit
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Honors
Five Memorial Sloan Kettering researchers have been named to Stand Up To Cancer's new Melanoma "Dream Team."
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.